Roivant Sciences Ltd. (ROIV) KPIs and segments
Close on Nov 18, 2026Market cap $27.98BP/E –Yield –
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Roivant Sciences · năm tài chính kết thúc ngày 31 tháng 3
Nhìn nhanh KPI của Roivant Sciences: 54 chỉ số vận hành, trong đó có Cumulative Vant-Sponsored Clinical Studies, Cumulative Clinical Trial Patient Enrollment và Immunovant, Inc. — Basic Ownership Stake, lấy từ 139 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Năm tài chính của Roivant Sciences kết thúc ngày 31 tháng 3 — Q2 FY2026 = CQ3 2026 (quý dương lịch).
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q4 FY2024 | Q3 FY2024 | Q2 FY2024 | Q1 FY2024 | Q4 FY2023 | Q3 FY2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)2 | |||||||||||||
Cumulative Vant-Sponsored Clinical Studies9 | 37 | 36 | 36 | 34 | 33 | 32 | 27 | 24 | 22 | 20 | 20 | 20 | |
Phase 3 Registrational Studies | 10 | 9 | 9 | 8 | 8 | 8 | 6 | 6 | 6 | 5 | 5 | 5 | |
Phase 2 Clinical Studies | 24 | 24 | 24 | 23 | 22 | 21 | 19 | 16 | 14 | 13 | 13 | 13 | |
Phase 1 Clinical Studies | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | |
Immunovant — Total Anti-FcRn Studies2 | 19 | 19 | 19 | 18 | 18 | 17 | 14 | 11 | 10 | 10 | 10 | 10 | |
IMVT-1402 (Imeroprubart) Studies | 8 | 8 | 8 | 7 | 7 | 7 | 4 | 1 | 0 | 0 | 0 | 0 | |
Batoclimab (IMVT-1401) Studies | 11 | 11 | 11 | 11 | 11 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | |
Priovant — Brepocitinib (LISRAYA) Studies | 6 | 6 | 6 | 5 | 5 | 5 | 4 | 4 | 4 | 2 | 2 | 2 | |
Pulmovant — Mosliciguat Studies | 4 | 3 | 3 | 3 | 2 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | |
Kinevant — Namilumab & Gimsilumab Studies | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | |
Dermavant — Tapinarof & Cerdulatinib Studies (Legacy) | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | |
New Vant-Sponsored Studies Initiated | 1 | 0 | 2 | 1 | 1 | 5 | 3 | 2 | 2 | 0 | 0 | 0 | |
Cumulative Clinical Trial Patient Enrollment9 | 4,746 | 4,370 | 4,370 | 3,656 | 3,636 | 3,610 | 2,813 | 2,475 | 2,100 | 1,724 | 1,724 | 1,724 | |
Phase 3 Patient Enrollment | 2,271 | 1,895 | 1,895 | 1,553 | 1,553 | 1,553 | 1,154 | 1,154 | 1,154 | 783 | 783 | 783 | |
Phase 2 Patient Enrollment | 2,407 | 2,407 | 2,407 | 2,035 | 2,015 | 1,989 | 1,599 | 1,261 | 886 | 881 | 881 | 881 | |
Phase 1 Patient Enrollment | 68 | 68 | 68 | 68 | 68 | 68 | 60 | 60 | 60 | 60 | 60 | 60 | |
Immunovant — Total Anti-FcRn Patient Enrollment2 | 2,359 | 2,359 | 2,359 | 1,987 | 1,987 | 1,961 | 1,340 | 1,002 | 762 | 762 | 762 | 762 | |
IMVT-1402 (Imeroprubart) Patient Enrollment | 1,571 | 1,571 | 1,571 | 1,199 | 1,199 | 1,199 | 578 | 240 | 0 | 0 | 0 | 0 | |
Batoclimab (IMVT-1401) Patient Enrollment | 788 | 788 | 788 | 788 | 788 | 762 | 762 | 762 | 762 | 762 | 762 | 762 | |
Priovant — Brepocitinib (LISRAYA) Patient Enrollment | 1,153 | 1,153 | 1,153 | 811 | 811 | 811 | 643 | 643 | 643 | 267 | 267 | 267 | |
Pulmovant — Mosliciguat Patient Enrollment | 539 | 163 | 163 | 163 | 143 | 143 | 135 | 135 | 0 | 0 | 0 | 0 | |
Kinevant — Namilumab & Gimsilumab Patient Enrollment | 371 | 371 | 371 | 371 | 371 | 371 | 371 | 371 | 371 | 371 | 371 | 371 | |
Dermavant — Clinical Trial Patient Enrollment (Legacy) | 324 | 324 | 324 | 324 | 324 | 324 | 324 | 324 | 324 | 324 | 324 | 324 | |
New Patient Enrollment Added in Initiated Trials | 376 | 0 | 714 | 20 | 26 | 797 | 338 | 375 | 376 | 0 | 0 | 0 | |
Immunovant, Inc. — Basic Ownership Stake(%)1 | 55.0% | 55.0% | 56.0% | 56.0% | 55.0% | 55.0% | 55.0% | 55.0% | |||||
Immunovant, Inc. — Fully Diluted Ownership Stake(%) | 52.0% | 52.0% | 52.0% | 52.0% | 50.0% | 48.0% | 49.0% | 49.0% | |||||
Priovant Therapeutics — Basic Ownership Stake(%)1 | 71.0% | 71.0% | 72.0% | 73.0% | 73.0% | 75.0% | 75.0% | 75.0% | |||||
Priovant Therapeutics — Fully Diluted Ownership Stake(%) | 65.0% | 65.0% | 66.0% | 66.0% | 65.0% | 67.0% | 68.0% | 68.0% | |||||
Pulmovant, Inc. — Basic Ownership Stake(%)1 | 95.0% | 97.0% | 97.0% | 98.0% | 98.0% | ||||||||
Pulmovant, Inc. — Fully Diluted Ownership Stake(%) | 90.0% | 90.0% | 90.0% | 91.0% | 91.0% | ||||||||
Genevant Sciences Ltd. — Basic Ownership Stake(%)1 | 83.0% | 83.0% | 83.0% | 83.0% | 83.0% | 83.0% | 83.0% | 83.0% | |||||
Genevant Sciences Ltd. — Fully Diluted Ownership Stake(%) | 64.0% | 64.0% | 64.0% | 64.0% | 64.0% | 65.0% | 65.0% | 65.0% | |||||
Covant Therapeutics — Basic Ownership Stake(%)1 | 96.0% | 96.0% | 94.0% | 95.0% | 95.0% | 100.0% | 100.0% | 100.0% | |||||
Covant Therapeutics — Fully Diluted Ownership Stake(%) | 90.0% | 91.0% | 91.0% | 91.0% | 90.0% | 87.0% | 87.0% | 86.0% | |||||
Arbutus Biopharma Corp. — Basic Ownership Stake(%)5 | 19.0% | 20.0% | 20.0% | 20.0% | 20.0% | 21.0% | 22.0% | 23.0% | |||||
Arbutus Biopharma Corp. — Fully Diluted Ownership Stake(%) | 19.0% | 19.0% | 19.0% | 19.0% | 19.0% | 19.0% | 19.0% | 20.0% | |||||
Arbutus Biopharma — Exact Voting Ownership Stake (Footnote XBRL)(%) | 19.0% | 20.0% | 20.0% | 20.0% | 20.0% | 20.0% | 20.0% | 20.0% | 21.0% | 21.0% | 22.0% | 23.0% | |
Arbutus Biopharma — Investment Fair Value (Level 1)($M) | 186 | 187 | 175 | 187 | 176 | 120 | 136 | 127 | 150 | 120 | 100 | 97.1 | |
Arbutus Biopharma — Unrealized Gain (Loss) on Investment($M) | -0.80 | 11.7 | -90.5 | 10.5 | 56.3 | -15.5 | -62.2 | -22.5 | 29.5 | 19.8 | 38.1 | 18.3 | |
Arbutus Biopharma — Period-End Common Share Price($) | 4.78 | 4.80 | 4.50 | 4.81 | 4.54 | 3.09 | 3.49 | 3.27 | 3.85 | 3.09 | 2.58 | 2.50 | |
Datavant Holdings — Minority Equity Ownership Stake(%)2 | 9.0% | 9.0% | 9.0% | 9.0% | 9.0% | 9.0% | 9.0% | 9.0% | 9.0% | 9.0% | 9.0% | 9.0% | |
Datavant Holdings — Investment Fair Value (Level 3)($M) | 319 | 258 | 233 | 247 | 236 | 164 | 167 | 163 | 162 | 143 | 148 | 136 | |
Datavant Holdings — Gain (Loss) on Investment($M) | 61.1 | 25 | -146 | 11.1 | 72.2 | -3.60 | -35.3 | 1.20 | 18.9 | 4.60 | 73.7 | -28.4 | |
Dermavant Sciences — Basic Ownership Stake (Legacy, Divested Q2 FY2024)(%)1 | 87.0% | 100.0% | 100.0% | ||||||||||
Dermavant Sciences — Fully Diluted Ownership Stake (Legacy)(%) | 82.0% | 86.0% | 85.0% | ||||||||||
Kinevant Sciences — Basic Ownership Stake (Legacy)(%)1 | 96.0% | 96.0% | 96.0% | ||||||||||
Lokavant — Basic Ownership Stake (Legacy)(%)1 | 57.0% | 57.0% | 57.0% | ||||||||||
Psivant Therapeutics — Basic Ownership Stake (Legacy)(%)1 | 48.0% | 48.0% | 100.0% | ||||||||||
Total Program-Specific R&D Expense($M)12 | 96.8 | 139 | 95.1 | 103 | 89.7 | 83.8 | 90.0 | 77.1 | 67.8 | ||||
Anti-FcRn Franchise — Endocrine Diseases R&D($M) | 22.5 | 42.9 | 26.3 | 19.8 | 24.9 | 19.3 | 16.8 | 15.5 | 14.9 | 15.9 | 6.88 | ||
Anti-FcRn Franchise — Neurological Diseases R&D($M) | 18.3 | 25.5 | 20.8 | 17.7 | 23.1 | 20.9 | 20.2 | 25.0 | 29.6 | 18.5 | 12.8 | ||
Anti-FcRn Franchise — Rheumatology Diseases R&D($M) | 9.90 | 22.3 | 12.9 | 14.1 | 13.6 | 8.20 | 6.70 | 8.20 | 9 | 0 | 0 | ||
Anti-FcRn Franchise — Dermatology Diseases R&D($M) | 0.60 | 7.50 | 4.10 | 3 | 8 | 5.10 | 5.70 | 5 | 4.90 | 0 | |||
Anti-FcRn Franchise — Other Clinical & Nonclinical R&D($M) | 0.27 | 2.61 | 0.19 | 0.46 | 0.32 | 2.39 | 1.75 | 0.04 | 1.13 | 6.40 | 4.89 | ||
Brepocitinib (LISRAYA) Program R&D($M) | 14.4 | 14.1 | 14.3 | 16.2 | 14.7 | 15.0 | 13.1 | 10.9 | 10.5 | 10.6 | 10.4 | ||
Mosliciguat Program R&D($M) | 19.1 | 13.0 | 9.83 | 10.4 | 7.47 | 8.39 | 5.88 | 4.70 | 6.18 | 2.98 | 2.01 | ||
Other Development & Discovery Programs R&D($M) | 11.8 | 11.1 | 13.4 | 13.4 | 11.2 | 10.2 | 14.0 | 14.6 | 13.7 | 15.5 | 12.3 | ||
Tapinarof (VTAMA) Program R&D (Legacy, Divested FY2024)($M) | 6.96 | 8.78 | |||||||||||
RVT-3101 (Telavant) Program R&D (Legacy, Divested FY2023)($M) | 0 | 0 | 0 | 5.65 | |||||||||
Namilumab Program R&D (Legacy)($M) | 3.13 | 3.49 | 4.38 | 3.28 | |||||||||
RVT-2001 Program R&D (Legacy)($M) | 0.03 | 0.22 | 1.66 | 1.90 | |||||||||
Unallocated R&D — Personnel-Related Expenses($M)2 | 33.3 | 46.4 | 41.4 | 40.7 | 42.5 | 38.3 | 33.6 | 35.2 | 37.6 | ||||
Unallocated R&D — Share-Based Compensation($M) | 7.97 | 8.72 | 7.65 | 18.1 | 11.0 | 11.1 | 9.65 | 9.69 | 9.91 | 10.5 | 9.76 | 6.91 | |
Unallocated R&D — Other Internal Expenses($M) | 7.70 | 7.86 | 10.7 | 9.68 | 9.64 | 9.79 | 9.58 | 9.97 | 10.8 | ||||
SG&A — Share-Based Compensation Expense($M)2 | 71.3 | 74.6 | 69.5 | 86.9 | 70.8 | 71.1 | 73.8 | 69.4 | 59.4 | 36.8 | 34.0 | 44.4 | |
SG&A — Personnel-Related Expenses($M) | 38.8 | 56.2 | 28.2 | 38.0 | 30.1 | 33.6 | 110 | 29.7 | |||||
SG&A — Other Operating & Commercial Launch Expenses($M) | 44.0 | 34.7 | 60.0 | 34.3 | 32.8 | 38.6 | 33.6 | 33.4 | |||||
Adjusted R&D Expense (Non-GAAP)($M) | 137 | 193 | 191 | 147 | 153 | 141 | 135 | 131 | 132 | 122 | 115 | ||
Adjusted SG&A Expense (Non-GAAP)($M) | 82.5 | 90.7 | 88.5 | 71.0 | 72.1 | 62.6 | 72.3 | 71.1 | 142 | 108 | 148 | ||
Adjusted Net Loss from Continuing Operations (Non-GAAP)($M) | -133 | -244 | -223 | -167 | -188 | -170 | -154 | -144 | -219 | -131 | -175 | ||
Litigation Settlement Gain (Moderna Global LNP Settlement)($M)1 | 0 | 0.40 | 0 | 0 | |||||||||
Litigation Settlement Receivable, Current($M) | 0 | 772 | 770 | 0 | |||||||||
Immunovant — Total Standalone R&D Expense($M)3 | 85.0 | 143 | 98.9 | 114 | 101 | 94.5 | 97.3 | 75.5 | 48.3 | ||||
Immunovant — Total Therapeutic Area-Specific R&D($M)5 | 51.5 | 101 | 55.1 | 69.9 | 56.0 | 53.6 | 59.6 | 40.8 | 24.6 | ||||
Endocrine Diseases R&D (Graves' Disease & TED)($M) | 22.5 | 42.9 | 19.8 | 24.9 | 19.3 | 15.5 | 14.9 | 15.9 | 6.88 | ||||
Neurological Diseases R&D (MG & CIDP)($M) | 18.3 | 25.5 | 17.7 | 23.1 | 20.9 | 25.0 | 29.6 | 18.5 | 12.8 | ||||
Rheumatology Diseases R&D (D2T RA & SjD)($M) | 9.86 | 22.3 | 14.1 | 13.6 | 8.21 | 8.18 | 9.05 | 0 | 0 | ||||
Dermatology Diseases R&D (CLE)($M) | 0.65 | 7.54 | 3.04 | 7.95 | 5.15 | 4.95 | 4.94 | 0 | |||||
Other Clinical & Nonclinical R&D($M) | 0.27 | 2.61 | 0.46 | 0.32 | 2.39 | 0.04 | 1.13 | 6.40 | 4.89 | ||||
Immunovant — Unallocated Personnel-Related & SBC R&D($M) | 24.1 | 33.5 | 32.2 | 32.6 | 34.5 | 29.5 | 26.3 | 24.5 | 17.3 | ||||
Immunovant — Unallocated Other R&D($M) | 9.40 | 8.30 | 11.6 | 11.7 | 10.7 | 11.4 | 11.3 | 10.2 | 6.47 | ||||
Immunovant — Standalone G&A Expense($M) | 19.1 | 17.7 | 17.3 | 15.4 | 17.5 | 26 | 20.2 | 19.8 | 18.5 | 18.8 | 14.8 | 13.2 | |
Immunovant — Total Standalone Operating Expenses($M) | 104 | 160 | 160 | 114 | 132 | 127 | 114 | 114 | 116 | 94.3 | 80.9 | 61.6 | |
Immunovant — Standalone Share-Based Compensation($M) | 13.3 | 13.8 | 11.1 | 12.7 | 13.4 | 18.5 | 11.7 | 11.7 | 12.7 | 13.5 | 9.70 | 10.2 | |
Immunovant — Standalone Net Loss($M) | -97.2 | -153 | -148 | -111 | -127 | -121 | -106 | -111 | -109 | -87.2 | -75.3 | -51.4 | |
Immunovant — Operating Cash Flow($M) | -83.2 | -124 | -95.1 | -92.3 | -103 | -117 | -111 | -100 | -88.6 | -76.2 | -59.7 | -47.1 | |
Immunovant — Standalone Cash & Cash Equivalents($M)2 | 722 | 798 | 902 | 995 | 522 | 599 | 714 | 375 | 473 | 560 | 635 | 691 | |
Immunovant — Accrued Professional & Clinical Fees($M) | 1.30 | 0.70 | 1.30 | 1.30 | 0.90 | 0.80 | 0.80 | 0.10 | 0.30 | 0.50 | 0.50 | 0.20 | |
Immunovant — Accrued Employee Bonuses($M) | 7.30 | 5.30 | 16.8 | 14.1 | 9.50 | 4.90 | 15.6 | 11.3 | 7.10 | 3.40 | 14.7 | 7.50 | |
Immunovant — Common Shares Outstanding(M)8 | 207 | 206 | 204 | 203 | 175 | 171 | 170 | 147 | 147 | 146 | 146 | 145 | |
Immunovant — Stock Options Outstanding(M) | 7.94 | 8.36 | 9.99 | 10.6 | 12.9 | 14.8 | 13.0 | 13.2 | 13.6 | 14.0 | 13.0 | 13.1 | |
Immunovant — Stock Options Exercisable(M) | 4.39 | 4.42 | 4.88 | 5.01 | 6.75 | 9.62 | 9.43 | 9.12 | 8.98 | 8.50 | 7.52 | 6.97 | |
Immunovant — Stock Options Granted(M) | 0.06 | 1.07 | 0.02 | 0.07 | 1.55 | 2.84 | 0.02 | 0.34 | 1.14 | 0.25 | 0.07 | ||
Immunovant — Stock Options Exercised(M) | 0.33 | 1.65 | 0.39 | 2.12 | 3.20 | 0.43 | 0.15 | 0.33 | 0.06 | 0.15 | 0.31 | ||
Immunovant — Options Weighted-Average Exercise Price($) | 16.41 | 16.45 | 15.22 | 15.07 | 14.23 | 12.62 | 12 | 11.97 | 11.56 | 11.50 | 9.85 | 9.36 | |
Immunovant — Options Aggregate Intrinsic Value($M) | 139 | 185 | 104 | 117 | 48.1 | 73.8 | 89 | 179 | 235 | 217 | 294 | 429 | |
Immunovant — Equity Plan Shares Available for Future Grant(M) | 6.75 | 6.58 | 7.82 | 7.63 | 7.38 | 8.59 | 6.03 | 5.94 | 6.05 | 5.68 | 2.09 | 2.18 | |
Immunovant — Antidilutive Securities Excluded from Diluted EPS(M) | 11.7 | 12.5 | 13.6 | 14.5 | 17.2 | 19.5 | 16.2 | 16.8 | 17.3 | 18.1 | 16.5 | 16.9 | |
Common Shares Repurchased & Retired(M)4 | 2.47 | 6.89 | 3.96 | 0 | 0 | 20.3 | 0 | 20.8 | 9.02 | 71.3 | |||
Share Repurchase Aggregate Cost($M) | 72.5 | 209 | 110 | 0 | 0 | 208 | 0 | 243 | 106 | 648 | |||
Remaining Share Repurchase Authorization($M) | 609 | 682 | 890 | 500 | 500 | ||||||||
At-the-Market (ATM) Equity Facility Remaining Capacity($M) | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | |
Tax Withholding & Excise Payments on Equity Settlements/Repurchases($M) | 21.1 | 51.4 | 8.80 | 23.9 | 6.50 | 9.50 | 7.50 | 8.60 | 8.50 | 12.7 | 28.6 | 3.30 | |
Common Shares Outstanding (Filing Cover Date)(M)1 | 725 | 722 | 719 | 716 | 695 | 683 | 680 | 714 | 728 | 740 | 739 | 806 | |
Common Shares Outstanding (Period-End Balance Sheet)(M) | 724 | 723 | 720 | 710 | 690 | 682 | 696 | 720 | 733 | 739 | 807 | 805 | |
Antidilutive Securities — Stock Options & Performance Options(M)7 | 68.1 | 71.0 | 76.1 | 97.4 | 129 | 136 | 139 | 142 | 148 | 54.7 | 54.7 | 65.5 | |
Antidilutive — Restricted Stock Units & Performance Stock Units(M) | 59.8 | 60.3 | 60.8 | 63.7 | 65.7 | 53.1 | 51.0 | 51.5 | 52.0 | 5.42 | 5.42 | 5.42 | |
Antidilutive — Nonvested Earn-Out Shares(M) | 0 | 0 | 0 | 0 | 3.08 | 3.08 | 3.08 | 3.08 | 3.08 | 3.08 | 3.08 | 3.08 | |
Antidilutive — March 2020 Capped Value Appreciation Rights (CVARs)(M) | 0 | 0 | 0 | 17.6 | 17.6 | 17.6 | 17.6 | 17.6 | 17.6 | 17.6 | 17.6 | 17.6 | |
Antidilutive — Other Stock-Based Awards & Instruments(M) | 0.39 | 0.42 | 1.17 | 3.67 | 4.06 | 4.49 | 4.73 | 5.03 | 5.03 | 3.92 | 3.92 | 4.15 | |
Antidilutive — November 2021 CVARs (Legacy)(M) | 0 | 0 | 0 | 0 | 0.35 | 0.71 | 1.07 | 0.20 | 0.25 | 0.36 | |||
Antidilutive — Public Warrants (Legacy, Redeemed FY2024)(M) | 0 | 0 | 0 | ||||||||||
Antidilutive — Private Placement Warrants (Legacy, Redeemed FY2024)(M) | 0 | 0 | 0 | ||||||||||
Marketable Debt Securities — Total Fair Value($M)9 | 2,565 | 2,594 | 2,873 | 2,789 | 1,803 | 2,172 | |||||||
Marketable Debt Securities — Total Amortized Cost($M) | 2,582 | 2,600 | 2,876 | ||||||||||
Marketable Debt Securities — Gross Unrealized Gains($M) | 0.03 | 0.03 | 0.54 | ||||||||||
Marketable Debt Securities — Gross Unrealized Losses($M) | 16.3 | 6.57 | 4.09 | ||||||||||
U.S. Treasury Securities — Fair Value($M)3 | 1,879 | 1,889 | 2,124 | 3,052 | 3,149 | 3,264 | 0 | ||||||
U.S. Treasury Securities — Amortized Cost($M) | 1,891 | 1,892 | 2,125 | 3,048 | 3,146 | 3,264 | 2,172 | ||||||
U.S. Treasury Securities — Gross Unrealized Gains($M) | 0 | 0.03 | 0.54 | 3.92 | 3.14 | 0.86 | 1.27 | ||||||
U.S. Treasury Securities — Gross Unrealized Losses($M) | 11.9 | 3.71 | 1.41 | 0 | 0.07 | 0.79 | 0.46 | ||||||
Corporate Debt Securities — Fair Value($M)3 | 668 | 705 | 748 | 0 | |||||||||
Corporate Debt Securities — Amortized Cost($M) | 673 | 708 | 751 | ||||||||||
Corporate Debt Securities — Gross Unrealized Gains($M) | 0.03 | 0 | 0 | ||||||||||
Corporate Debt Securities — Gross Unrealized Losses($M) | 4.36 | 2.86 | 2.68 | ||||||||||
Cash Equivalents — Money Market Funds (Level 1)($M) | 1,476 | 1,171 | 1,375 | 1,386 | 1,135 | 2,622 | |||||||
Marketable Debt Securities — Contractual Maturities Within 1 Year($M) | 1,452 | 1,645 | 2,145 | ||||||||||
Marketable Debt Securities — Contractual Maturities 1 to 5 Years($M) | 1,114 | 949 | 727 | ||||||||||
Net Accretion of Discounts on Marketable Securities($M) | 4.90 | 5.70 | 6.40 | 0.90 | |||||||||
Financial Assets Measured at Fair Value — Total($M)4 | 4,546 | 4,210 | 4,655 | 4,872 | 2,924 | ||||||||
Fair Value Hierarchy — Level 1 Financial Assets($M) | 1,661 | 1,358 | 1,550 | 1,573 | 2,757 | ||||||||
Fair Value Hierarchy — Level 2 Financial Assets($M) | 2,565 | 2,594 | 2,873 | 3,052 | 0 | ||||||||
Fair Value Hierarchy — Level 3 Financial Assets($M) | 319 | 258 | 233 | 247 | 167 | ||||||||
Financial Liabilities Measured at Fair Value — Total($M) | 0 | 0 | 0 | ||||||||||
Cash, Cash Equivalents & Restricted Cash($M)3 | 1,650 | 1,261 | 1,431 | 1,489 | 1,247 | 1,249 | 2,726 | 2,002 | 1,970 | 5,693 | 6,506 | 6,686 | |
Restricted Cash — Current($M) | 0 | 4.20 | 3.86 | 2.61 | 2.26 | 2.26 | 2.36 | 3.10 | 3.11 | 5.41 | 3.07 | 5.17 | |
Restricted Cash — Non-Current($M) | 7.32 | 7.89 | 7.89 | 7.89 | 7.89 | 7.89 | 7.89 | 7.89 | 8.17 | 9.38 | 8.17 | 9.48 | |
Accrued Interest Receivable($M) | 21.6 | 21.6 | 19.6 | 12.1 | 23.2 | 13.9 | 22.7 | 27.4 | 18.9 | ||||
Share-Based Compensation — Subsidiary Equity Incentive Plans($M)7 | 14 | 14.8 | 11.3 | 38.4 | 14.4 | 19.3 | 14 | 13.5 | 13.9 | 14.7 | 11 | 20.2 | |
Subsidiary Share-Based Awards Vested & Exercised (Equity Impact)($M) | 6.40 | 23.6 | 21.6 | 25.1 | 3.60 | 2.60 | 0.80 | 0.70 | |||||
Cash Proceeds from Stock Option Exercises($M) | 25.4 | 76.0 | 51.2 | 119 | 68.3 | 30.1 | 12.6 | 28.1 | 6.62 | 2.27 | 3.29 | 8.88 | |
Roivant Stock Options Outstanding (RSL Plans)(M) | 68.1 | 71.0 | 76.1 | 97.4 | 129 | 136 | 139 | 142 | 148 | 150 | 147 | ||
Roivant Stock Options Exercisable (RSL Plans)(M) | 63.5 | 65.5 | 69.6 | 111 | 111 | 107 | 108 | 105 | |||||
Unvested Restricted Stock Units (RSL Equity Plans)(M) | 11.6 | 12.1 | 12.6 | 0 | 0 | 0 | 0.35 | 0.71 | 1.07 | 1.43 | 1.78 | ||
Unvested Performance Stock Units (RSL Equity Plans)(M) | 48.2 | 48.2 | 48.2 | 48.8 | 48.8 | 36.9 | 36.9 | 5.42 | |||||
Forfeited Performance Stock Units (RSL Equity Plans)(M) | 0 | 0 | 0.58 | 0 | |||||||||
Total Accrued Current Liabilities($M)5 | 188 | 169 | 206 | 118 | 108 | 88.7 | 114 | 104 | 112 | 138 | 119 | 122 | |
Accrued Clinical Trial & R&D Expenses($M) | 106 | 113 | 92.7 | 55.7 | 58.9 | 49.8 | 45.8 | 53.5 | 56.3 | 46.5 | 37.7 | 43.6 | |
Accrued Employee Compensation & Benefits($M) | 55.6 | 40.8 | 87.3 | 38.1 | 26.4 | 26.5 | 53.9 | 39.3 | 38.8 | 37.8 | 49.9 | 41.4 | |
Other Accrued Current Liabilities($M) | 26.3 | 14.5 | 25.7 | 24.2 | 23 | 12.4 | 14.6 | 11.6 | 16.3 | 26.3 | 31.8 | 20.3 | |
Income Taxes Payable — Current($M) | 59.1 | 74.2 | 45.7 | 7.17 | 0.42 | 0.58 | 5.41 | 23.4 | 9.77 | 25.2 | |||
Income Taxes Payable — Non-Current($M) | 0 | 0 | 38.7 | 0 | |||||||||
Operating Lease Right-of-Use (ROU) Assets($M)3 | 77.3 | 78.9 | 80.4 | 83.6 | 85.1 | 87.1 | 89 | 90.9 | 43 | 45.3 | 44 | 46.9 | |
Operating Lease Liabilities — Current($M) | 13.8 | 12.4 | 11.1 | 10.4 | 9 | 9.40 | 9.80 | 9.80 | 9.50 | 9.50 | 9 | 10.5 | |
Operating Lease Liabilities — Non-Current($M) | 92.8 | 94.8 | 96.3 | 98.5 | 89.8 | 90.3 | 90.3 | 90.5 | 43.2 | 45.9 | 45 | 47.1 | |
Operating Lease ROU Asset Amortization($M) | 1.54 | 1.39 | 1.86 | 2.53 | 1.94 | 1.94 | 1.97 | 1.71 | 1.58 | 1.58 | 1.80 | 1.73 | |
Gross Deferred Tax Assets1 | |||||||||||||
Effective Income Tax Rate (Continuing Operations)(%) | 3.8% | 1.3% | -50.4% | -4.9% | -2.7% | -1.7% | -7.1% | 0.2% | -10.0% | -60.9% | 0.5% | 0.6% | |
Arbutus Biopharma Corp. (ABUS) — Collaboration & License Revenue($M)7 | 0.30 | 1.01 | 179 | 0.53 | 10.7 | 1.76 | 1.34 | 1.73 | 1.53 | ||||
Arbutus Biopharma Corp. (ABUS) — R&D Expense($M) | 2.62 | 2.90 | 4.12 | 5.78 | 5.50 | 8.96 | 14.3 | 15.6 | 15.4 | ||||
Arbutus Biopharma Corp. (ABUS) — G&A Expense($M) | 7.96 | 3.87 | 5.89 | 3.04 | 3.33 | 5.83 | 4.54 | 7.55 | 5.31 | ||||
Arbutus Biopharma Corp. (ABUS) — Net Income (Loss)($M) | 59.1 | -5.14 | 170 | -7.74 | 2.52 | -24.5 | -19.7 | -19.8 | -17.9 | ||||
Arbutus Biopharma Corp. (ABUS) — Cash & Cash Equivalents($M) | 264 | 19.2 | 23.7 | 18.0 | 22.4 | 37.4 | 37.1 | 36.3 | 31.9 | 62.8 | 43.1 | 26.3 | |
Arbutus Biopharma Corp. (ABUS) — Marketable Securities($M) | 73.3 | 73.5 | 71.5 | 73.5 | 71.3 | 60.7 | 75.6 | 86.3 | 96.0 | 79.2 | 86.1 | 99.7 | |
Arbutus Biopharma Corp. (ABUS) — Common Shares Outstanding(M) | 199 | 198 | 197 | 193 | 192 | 192 | 191 | 190 | 189 | 189 | 180 | 170 | |
Arbutus Biopharma Corp. (ABUS) — Antidilutive Securities(M) | 8.24 | 9.14 | 10.4 | 14 | 14.4 | 14.0 | 15.6 | 16.9 | 22.6 | 20.4 | |||
U.S. Real PCE: Pharmaceutical & Other Medical Products (SAAR)($M) | 3,858,670 | 3,790,290 | 3,699,900 | 3,666,990 | 3,614,850 | 3,529,830 | 3,464,650 | 3,417,830 | 3,358,240 | 3,288,220 | 3,244,360 | 3,159,380 | |
Consolidated Revenue, Net($M)11 | 35.1 | 1.40 | 2.50 | 2 | 1.60 | 2.20 | 7.60 | 9 | 4.50 | 8 | 9 | 15.6 | |
Consolidated R&D Expense (GAAP)($M) | 146 | 202 | 199 | 165 | 165 | 153 | 145 | 142 | 143 | 121 | 108 | 108 | |
Consolidated SG&A Expense (GAAP)($M) | 154 | 166 | 158 | 175 | 143 | 134 | 147 | 142 | 203 | 149 | 170 | 197 | |
Operating Income (Loss) (GAAP)($M) | -268 | -366 | 415 | -339 | -306 | -285 | -285 | -274 | -342 | -102 | -207 | 5,128 | |
Interest Income($M) | 41.6 | 36.9 | 41.2 | 43.3 | 45.3 | 48.3 | 54.6 | 61.9 | 69.8 | ||||
Change in Fair Value / Gain on Investments($M) | 60.3 | 36.6 | -25.9 | 21.6 | 129 | -19.1 | 12.9 | -21.3 | 48.4 | 15.2 | 15.9 | -10.5 | |
Income (Loss) from Continuing Operations($M) | -207 | -291 | 303 | -266 | -114 | -274 | -207 | -158 | -187 | 6 | -64 | 5,155 | |
Income (Loss) from Discontinued Operations, Net of Tax($M) | 15.8 | 0 | 0 | 0 | 0 | 0 | 327 | -43.1 | 89.1 | -87.5 | -58.5 | ||
Net Income (Loss) Attributable to Noncontrolling Interests($M) | 54.4 | -101 | 52.8 | -47.8 | -52.5 | -50.6 | -45.9 | -51.3 | -49.7 | -37.8 | -31.4 | -23.5 | |
Net Income (Loss) Attributable to Roivant Sciences Ltd.($M) | -192 | -190 | 303 | -266 | -114 | -223 | -207 | 169 | -230 | 95.3 | -151 | 5,096 | |
Diluted Earnings (Loss) Per Share($) | -0.27 | -0.26 | -0.38 | -0.17 | -0.33 | 0.23 | -0.31 | 0.12 | 6.03 | ||||
Weighted-Average Diluted Shares(M) | 723 | 721 | 697 | 681 | 680 | 723 | 735 | 782 | 844 | ||||
Cash, Cash Equivalents & Short-Term Investments($M)8 | 4,208 | 3,842 | 4,292 | 4,530 | 4,386 | 4,503 | 4,887 | 5,147 | 5,387 | 6,495 | |||
Cash & Cash Equivalents($M) | 1,642 | 1,249 | 1,419 | 1,478 | 1,237 | 1,239 | 2,715 | 1,991 | 1,959 | 5,679 | 6,495 | 6,671 | |
Short-Term Marketable Securities($M) | 2,565 | 2,594 | 2,873 | 3,052 | 3,149 | 3,265 | 2,172 | 3,156 | 3,428 | 0 | |||
Property, Plant & Equipment, Net($M) | 10.9 | 11.3 | 12 | 13.4 | 25.7 | 14.9 | 12.1 | 13.6 | 13.7 | 17.8 | 15.3 | 21.9 | |
Total Assets($M) | 4,976 | 5,307 | 5,709 | 5,225 | 5,063 | 5,033 | 5,437 | 5,792 | 6,206 | 6,496 | 7,223 | 7,313 | |
Total Liabilities($M) | 380 | 385 | 416 | 251 | 257 | 217 | 250 | 256 | 626 | 601 | 774 | 728 | |
Shareholders' Equity Attributable to Roivant Sciences Ltd.($M) | 4,020 | 4,231 | 4,527 | 4,269 | 4,362 | 4,346 | 4,688 | 5,190 | 5,153 | 5,435 | 5,969 | 6,090 | |
Noncontrolling Interests (Balance Sheet)($M) | 575 | 691 | 765 | 705 | 443 | 470 | 500 | 347 | 427 | 460 | 480 | 495 | |
Total Shareholders' Equity($M) | 4,596 | 4,922 | 5,292 | 4,974 | 4,806 | 4,816 | 5,187 | 5,536 | 5,580 | 5,895 | 6,449 | 6,585 | |
Operating Cash Flow($M)4 | 594 | -271 | -164 | -197 | -186 | -204 | -173 | -207 | -267 | -193 | -109 | -211 | |
Capital Expenditures($M) | 0.21 | 0.42 | 1.26 | -4.93 | 7.85 | 4.04 | 0.81 | 1.83 | 1 | 0.96 | 0.35 | 0.35 | |
Share-Based Compensation (Cash Flow)($M) | 79.3 | 83.3 | 77.2 | 105 | 81.8 | 82.2 | 83.5 | 83.7 | 71.7 | 50.2 | 46.7 | 54.3 | |
Investing Cash Flow($M) | 42.5 | 281 | 174 | 110 | 120 | -1,086 | 1,074 | 454 | -3,294 | -1 | 6.90 | 5,233 | |
Financing Cash Flow($M) | -249 | -182 | -68.8 | 328 | 62.6 | -188 | -177 | -273 | -109 | -661 | -32.6 | 237 | |
4 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Fiscal calendar & Vant operating structure: Roivant Sciences Ltd. (NASDAQ: ROIV, CIK 0001635088) ends its fiscal year on March 31 and names each fiscal year after the calendar year in which it begins (FY2025 = April 1, 2025 through March 31, 2026; Q1 FY2026 ended June 30, 2026; Q2 FY2026 ended September 30, 2026). Roivant develops and commercializes medicines through focused operating subsidiaries ('Vants'), led by Priovant Therapeutics (LISRAYA / brepocitinib, FDA-approved in August 2026 for adult dermatomyositis), Immunovant, Inc. (NASDAQ: IMVT — anti-FcRn antibodies IMVT-1402 / imeroprubart and batoclimab), Pulmovant, Inc. (mosliciguat in PH-ILD), and Genevant Sciences Ltd. (LNP delivery platform & mRNA patent portfolio).
- Core operational & R&D metrics (Groups 1–3) track: (1) Clinical Trial Pipeline & Patient Enrollment across 37 Vant-sponsored clinical studies and 4,746 cumulative enrolled/target patients registered on ClinicalTrials.gov through Q2 FY2026, disaggregated by clinical phase and by Vant/molecule; (2) Roivant's Basic and Fully Diluted percentage equity ownership across each active and legacy Vant alongside fair value and ownership stakes in equity-method affiliates Arbutus Biopharma Corp. and Datavant Holdings; and (3) Program-specific R&D investment across five Anti-FcRn therapeutic areas, brepocitinib, mosliciguat, and discovery programs, unallocated personnel and share-based compensation, Non-GAAP Adjusted R&D and SG&A reconciliations, LISRAYA commercial launch net product revenue ($31.0M in Q2 FY2026), and Genevant's Moderna global LNP litigation settlement.
- Subsidiary, capital allocation & benchmark metrics (Groups 4–8) present: (4) Standalone SEC disclosures of publicly traded consolidated subsidiary Immunovant, Inc. (CIK 0001764013, ~55% basic / 52% diluted ownership), including therapeutic-area R&D, $722.3M standalone cash, stock option rollforwards, and 315 full-time employees; (5) Share repurchase execution across 10 consecutive quarters (128.4M shares for $1,293.2M in FY2024; 24.2M shares for $318.1M in FY2025; 9.4M shares for $281.2M in 6M FY2026 with $609.3M remaining authorization), $2,565.3M marketable debt securities portfolio by instrument and maturity, and antidilutive securities; (6) Subsidiary equity plan SBC, accrued clinical liabilities, operating leases, deferred tax attributes ($541M+ gross DTA), consolidated workforce (721 full-time employees), and DEF 14A Pay Versus Performance; (7) Standalone quarterly results of affiliate Arbutus Biopharma Corp. (CIK 0001447028) and U.S. pharmaceutical macro benchmarks from FRED; and (8) Consolidated GAAP financial context.
- Methodology: Under U.S. GAAP, Roivant Sciences Ltd. (a Bermuda holding company) does not publish quarterly parent-only operating financial statements, so no Consolidated − Parent Standalone subtraction is performed; instead, standalone filings of publicly traded subsidiary Immunovant, Inc. (IMVT) and affiliate Arbutus Biopharma Corp. (ABUS) are reported directly. All figures are strictly as published, except period-splitting derivations (Q4 = full year − 9M; Q2 = 6M − Q1; Q3 = 9M − 6M) shown in italic with their exact formula.
Không hiện vì thiếu các kỳ gần đây (10)
- LISRAYA (brepocitinib) commercial net product revenue ($31.0M in Q2 FY2026), License, milestone and other revenue disaggregation ($4.2M in Q2 FY2026), commercial cost of revenues ($3.3M in Q2 FY2026), commercial inventory ($12.1M at Q2 FY2026), specialty pharmacy customer concentration (82% Customer A and 18% Customer B in Q2 FY2026), and launch callouts ('hundreds of patients on paid drug', 'many hundreds of active prescribers'): following Dermavant's divestiture in Q2 FY2024, Roivant had no continuing commercial product until FDA approval of LISRAYA in late August 2026 (5 weeks before Q2 FY2026 quarter-end), leaving disaggregated commercial product lines with only 1 active post-launch quarter (omitted in Q4 FY2025 and Q1 FY2026 filings), fewer than the required 3 consecutive quarters; consolidated net revenue ($35.1M in Q2 FY2026) is included in Group 8.
- Anti-FcRn franchise contractual costs related to batoclimab program discontinuation ($39.0M in FY2025 vs. $0 in FY2024 and FY2023): one-time FY2025 charge without recurring quarterly series through Q2 FY2026.
- Early-stage divested or wound-down Vants with fewer than 3 recent periods or discontinued pre-FY2023 without recurring updates (Alyvant, Aruvant, Cytovant, Lysovant, Sio Gene Therapies, Affivant, Hemavant, VantAI): excluded or superseded as Roivant consolidated its active clinical portfolio around Priovant, Immunovant, Pulmovant, and Genevant.
- Clinical trial efficacy & biomarker readouts (IMVT-1402 D2T RA ACR20/50/70 response rates, CLARITY-1/2 NIU treatment failure hazard ratios & steroid-free quiescence %, PHocus mosliciguat PVR reduction & 6MWD meters, VALOR DM TIS scores) and epidemiological prevalence estimates (~85,000 U.S. D2T RA, 70,000–190,000 U.S. NIU, ~40,000 CS, ~100,000 LPP): cohort-specific trial endpoints or static disease prevalence constants rather than periodic operating time series.
- One-time M&A and litigation deal parameters: Organon Dermavant transaction milestones (up to $1.2B total: $175M upfront, $75M AD approval milestone, up to $950M commercial milestones, 30% royalty above $1B sales starting 2027), Roche Telavant $7.1B upfront + $150M milestone parameters, and Moderna $1.3B contingent Section 1498 appellate tranche.
- Approximate / bound-only disclosures ('hundreds of patients on paid drug', 'over 275,000 patients treated', 'more than 2,000 subjects', 'up to $1.0 billion', 'up to 300,000 patients'): excluded because bound expressions are not exact point observations.
- External Peer Affiliate & U.S. Pharmaceutical Macro Benchmarks › Arbutus Biopharma Corp. (ABUS) — Collaboration & License Revenue › Arbutus Biopharma Corp. (ABUS) — Share-Based Compensation
- External Peer Affiliate & U.S. Pharmaceutical Macro Benchmarks › Arbutus Biopharma Corp. (ABUS) — Collaboration & License Revenue › Arbutus Biopharma Corp. (ABUS) — Operating Cash Flow
- Consolidated GAAP Financial Context › Cash, Cash Equivalents & Short-Term Investments › Long-Term Investments
- Consolidated GAAP Financial Context › Operating Cash Flow › Cash Paid for Share Repurchases
Dữ liệu cập nhật 2026-11-16.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Clinical Trial Pipeline & Patient Enrollment (Key #1)
Vant Portfolio Equity Ownership & Strategic Affiliates (Key #2)
- Immunovant, Inc. — Basic Ownership Stake (%)18 kỳ
- Priovant Therapeutics — Basic Ownership Stake (%)15 kỳ
- Pulmovant, Inc. — Basic Ownership Stake (%)5 kỳ
- Genevant Sciences Ltd. — Basic Ownership Stake (%)18 kỳ
- Covant Therapeutics — Basic Ownership Stake (%)13 kỳ
- Arbutus Biopharma Corp. — Basic Ownership Stake (%)18 kỳ
- Datavant Holdings — Minority Equity Ownership Stake (%)18 kỳ
- Dermavant Sciences — Basic Ownership Stake (Legacy, Divested Q2 FY2024) (%)13 kỳ
- Telavant Holdings — Basic Ownership Stake (Legacy, Divested Q3 FY2023) (%)3 kỳ
- Kinevant Sciences — Basic Ownership Stake (Legacy) (%)13 kỳ
- Lokavant — Basic Ownership Stake (Legacy) (%)13 kỳ
- Psivant Therapeutics — Basic Ownership Stake (Legacy) (%)8 kỳ
- Proteovant Therapeutics — Basic Ownership Stake (Legacy) (%)8 kỳ
Program-Specific R&D, Commercial Launch & Non-GAAP Operations (Key #3)
- Total Program-Specific R&D Expense ($M)20 kỳ
- Unallocated R&D — Personnel-Related Expenses ($M)20 kỳ
- SG&A — Share-Based Compensation Expense ($M)22 kỳ
- Adjusted R&D Expense (Non-GAAP) ($M)20 kỳ
- Adjusted SG&A Expense (Non-GAAP) ($M)20 kỳ
- Adjusted Net Loss from Continuing Operations (Non-GAAP) ($M)20 kỳ
- Litigation Settlement Gain (Moderna Global LNP Settlement) ($M)4 kỳ
Immunovant, Inc. (NASDAQ: IMVT) — Consolidated Public Subsidiary
- Immunovant — Total Standalone R&D Expense ($M)22 kỳ
- Immunovant — Standalone G&A Expense ($M)26 kỳ
- Immunovant — Total Standalone Operating Expenses ($M)26 kỳ
- Immunovant — Standalone Share-Based Compensation ($M)26 kỳ
- Immunovant — Standalone Net Loss ($M)26 kỳ
- Immunovant — Operating Cash Flow ($M)26 kỳ
- Immunovant — Standalone Cash & Cash Equivalents ($M)26 kỳ
- Immunovant — Common Shares Outstanding (M)26 kỳ
- Immunovant — Gross Deferred Tax Assets ($M)6 kỳ
- Immunovant — Full-Time Permanent Employees4 kỳ
Share Repurchases, Marketable Securities Portfolio & Dilution
- Common Shares Repurchased & Retired (M)10 kỳ
- Common Shares Outstanding (Filing Cover Date) (M)22 kỳ
- Antidilutive Securities — Stock Options & Performance Options (M)24 kỳ
- Marketable Debt Securities — Total Fair Value ($M)6 kỳ
- Financial Assets Measured at Fair Value — Total ($M)5 kỳ
- Cash, Cash Equivalents & Restricted Cash ($M)26 kỳ
Equity Plans, Accrued Liabilities, Leases, Taxes & Workforce
External Peer Affiliate & U.S. Pharmaceutical Macro Benchmarks
- Arbutus Biopharma Corp. (ABUS) — Collaboration & License Revenue ($M)20 kỳ
- U.S. PPI: Pharmaceutical Preparation Manufacturing (Index)82 kỳ
- U.S. CPI: Medical Care Commodities (Index)81 kỳ
- U.S. CPI: Medical Care Services (Index)81 kỳ
- U.S. Retail Sales: Pharmacies & Drug Stores (SA) ($M)80 kỳ
- U.S. Employment: Health Care Sector (Thousands) (M)82 kỳ
- U.S. Real PCE: Pharmaceutical & Other Medical Products (SAAR) ($M)26 kỳ
Consolidated GAAP Financial Context
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Roivant Sciences
- Form 10-Q (filed 2026-11-09) ↗
- Form 10-K (roiv-20260331.htm, filed 2026-05-20) ↗
- Form 10-Q (roiv-20260930.htm, filed 2026-11-09) ↗
- Form 10-K (filed 2026-05-20) ↗
- Immunovant, Inc. Form 10-Q (filed 2026-11-09) ↗
- Immunovant, Inc. Form 10-K (filed 2026-05-20) ↗
- ClinicalTrials.gov API v2 (Roivant Vant Sponsors: Immunovant, Priovant, Pulmovant, Kinevant, Dermavant) ↗
- Form 10-Q (ef20030921_10q.htm, filed 2024-08-09) ↗
- Form 10-K (ef20026301_10k.htm, filed 2024-05-30) ↗
- Form 10-K (brhc20054745_10k.htm, filed 2023-06-28) ↗
- Form 8-K (q2fy2026roivantearningsrel.htm, filed 2026-11-09) ↗
- Form 8-K (q4fy2025roivantearningsrel.htm, filed 2026-05-20) ↗
See a number that looks wrong?